Prolium Bioscience
Latest round
- Series A
Last raised
- Mar 2026
Total raised
- $50M
Investors
- 1
About Prolium Bioscience
Prolium Bioscience, Inc.Founded in 2025 and headquartered in New York, US, Prolium Bioscience, Inc. specializes in creating advanced therapeutics for autoimmune disorders.Prolium Bioscience specializes in developing innovative therapies aimed at treating severe autoimmune diseases, focusing on its flagship product, PRO-203, a CD20xCD3 T-Cell Engager. This advanced therapeutic engages T-cells to target B-cells, modulating the immune response in patients. The company serves a diverse client base including healthcare providers and research institutions, targeting markets in North America and Europe where autoimmune disorders are prevalent.Prolium Bioscience's revenue model is structured around the commercialization of its therapeutic products, particularly through partnerships with healthcare providers and research institutions. Healthcare organizations procure PRO-203 for clinical use, reflecting the complexity of its biopharmaceutical innovations.In March 2026, Prolium Bioscience, Inc. The company is focused on expanding its product offerings and plans to enter new markets in Europe and North America by 2027.
Who invested in Prolium Bioscience
1 investor across 1 round
See all investors in Prolium Bioscience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 3, 2026
Amount
$50M
Investors
Questions about Prolium Bioscience
Who invested in Prolium Bioscience?
Prolium Bioscience has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Prolium Bioscience raised?
Prolium Bioscience has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Prolium Bioscience last raise money?
Prolium Bioscience's most recent round on record is a Series A, in Mar 2026.
What does Prolium Bioscience do?
Prolium Bioscience is a biotechnology company.
Where is Prolium Bioscience headquartered?
Prolium Bioscience is headquartered in New York, US.
Which VCs invest in companies like Prolium Bioscience?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Prolium Bioscience's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Prolium Bioscience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.